Compare HUBS & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBS | WST |
|---|---|---|
| Founded | 2005 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 20.2B |
| IPO Year | 2014 | N/A |
| Metric | HUBS | WST |
|---|---|---|
| Price | $358.39 | $271.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 30 | 7 |
| Target Price | ★ $616.87 | $338.00 |
| AVG Volume (30 Days) | ★ 776.3K | 681.1K |
| Earning Date | 02-11-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.32% |
| EPS Growth | N/A | ★ 0.17 |
| EPS | N/A | ★ 6.75 |
| Revenue | $2,987,698,000.00 | ★ $3,017,900,000.00 |
| Revenue This Year | $20.87 | $7.01 |
| Revenue Next Year | $16.03 | $6.20 |
| P/E Ratio | ★ N/A | $40.42 |
| Revenue Growth | ★ 19.21 | 4.92 |
| 52 Week Low | $344.41 | $187.43 |
| 52 Week High | $881.13 | $348.90 |
| Indicator | HUBS | WST |
|---|---|---|
| Relative Strength Index (RSI) | 37.23 | 46.13 |
| Support Level | $376.22 | $267.82 |
| Resistance Level | $405.11 | $283.45 |
| Average True Range (ATR) | 14.51 | 7.24 |
| MACD | -2.80 | -0.51 |
| Stochastic Oscillator | 9.51 | 16.51 |
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.